Financials in USD. Standardized financial statements.
A compact view of how Linike Medical Group Ltd turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $10.68M | $13.05M | $8.95M | $0 | $0 | $0 | $0 | $0 | $69,301 |
| Revenue Growth? | -18.2% | +45.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $132,236 | $55,121 | $65,111 | $0 | $0 | $0 | $0 | $593 | $26,987 |
| Gross Profit? | $10.54M | $12.99M | $8.89M | $0 | $0 | $0 | $0 | -$593 | $42,314 |
| Gross Margin? | +98.8% | +99.6% | +99.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +61.1% |
| Operating Expenses? | $7.46M | $13.24M | $7.90M | $65,979 | $29,861 | $88,566 | $1,075 | $214,511 | $130,269 |
| Operating Income? | $3.09M | -$244,879 | $991,040 | -$65,980 | -$29,860 | -$88,570 | -$1,080 | -$215,100 | -$87,960 |
| EBITDA? | $3.22M | -$189,758 | $1.06M | -$65,980 | -$29,860 | -$88,570 | -$1,080 | -$214,511 | -$85,800 |
| Income Before Tax | $3.09M | -$244,879 | $991,040 | -$65,979 | -$29,861 | -$88,566 | -$1,075 | -$427,769 | -$88,353 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$3 | -$3 |
| Net Income? | $3.09M | -$244,879 | $991,040 | -$65,979 | -$29,861 | -$88,566 | -$1,075 | -$427,769 | -$88,353 |
| EPS? | $0.00 | $-0.00 | $0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-203.80 | $-0.00 |
| Diluted EPS? | $0.00 | $-0.00 | $0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-203.80 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality